Search PubMedSearch

Biomedical subjects

B Helpap

Publications and source records attributed to B Helpap.

At least 19 recordsLinked to original sources

Nucleolar organizer regions in low- and high-grade carcinomas of the prostate.

The number of silver-stained nucleolar organizer regions (AgNORs) and the status of nucleoli were studied in biopsies from 10 cases of normoglandular prostatic tissue and the findings were compared with the results obtained for 10 cases of hyperplastic prostatic tissue (BPH) and 74 cases of prostatic carcinoma of various grades of malignancy. There was an increase in the number of AgNORs detected between the grade of malignancy found in highly versus poorly differentiated carcinomas of the prostate. Furthermore AgNOR values differed significantly among the groups compared (P < 0.001). The nucleolar status confirmed these differences. In addition, the significantly different survival of patients suffering from prostatic carcinomas support our idea of subdividing GII carcinomas into group IIa (low risk) and group IIb (high risk). This subgrading implies the possibility of preoperatively identifying patients with a prostate carcinoma of high malignancy within the GII carcinoma group.

Carcinoma

Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma.

Atypical glandular proliferations of the prostate are found in combination with prostate carcinomas but also with benign prostatic hyperplasia (BPH). These atypical glandular lesions that mimic glandular carcinoma within the anterocentral part of the prostate (transition zone) are named "atypical adenomatous hyperplasia (AAH)." The term for atypical ductal and acinar mainly papillary and/or cribriform proliferations in the peripheral zone is "prostatic intraepithelial neoplasia (PIN)." In this study the significance of the status of nucleoli and the number of silver-stained nucleolar organizing regions (AgNOR) as a method for measuring proliferative activity was investigated in biopsies of AAH, PIN and carcinomas of different grades of malignancy. The aim was to prove whether there are relationships of AAH to low grade carcinomas on the one hand and of PIN to high grade carcinomas on the other hand. The frequency of nuclei with small nucleoli was low in BPH (0.6%). The values increased to 8.3% in AAH, and 28.7% in PIN. The frequency of nuclei with prominent nucleoli in low grade carcinomas was 41.7% and in high grade carcinomas 81.1%. Usually, one single nucleolus was found per nucleus. Multiple prominent nucleoli were found in high grade carcinomas and in some cases of high grade PIN only. The result of AgNOR-analysis was similar: low numbers in BPH, low to moderate values in AAH, moderate values in low grade carcinomas and high values in PIN, as well as high grade carcinomas. Besides correlation between topography, histology and cytology, the similarities of nucleolar and AgNOR-analysis between PIN and high grade carcinomas support the idea that PIN is the precursor of the peripheral prostatic carcinoma. The histological, cytological and cell kinetical features of AAH are intermediate between BPH and low grade carcinoma of the prostate. Therefore, the findings to date are inconclusive and further follow up studies are necessary to prove if AAH may be a precursor of transition zone carcinoma of the prostate.

Adenocarcinoma

Nucleolar and argyrophilic nucleolar organizer region counts in urothelial carcinomas with special emphasis on grade II tumors.

Prognostic assessment of bladder carcinomas of intermediate differentiation is difficult. This study therefore investigated the prognostic values of nucleolar status and silver staining of argyrophilic nucleolar organizer regions (AgNORs) in grade II bladder carcinomas. In biopsies from 34 grade II transitional cell carcinomas of the urinary bladder the number of nuclei with nucleoli, the location of nucleoli within the nucleus and the number of AgNORs were determined in 1000 or 200 nuclei per section respectively. Ten biopsies showing normal urothelium, 18 cases with mild to severe atypia, 27 grade I, 34 grade II and 12 grade III transitional cell carcinomas were also studied. Significantly differing nucleolar and AgNOR values were found comparing normal urothelium/grade I carcinomas with severe urothelial atypia/grade III carcinomas. Grade II carcinomas, however, were inhomogeneous. One subgroup had nucleolar and AgNOR values resembling grade I carcinomas while the second group had values similar to those of grade III carcinomas. This subdivision of grade II carcinomas correlates with results reported for DNA-cytometry. The results suggest a subdivision of patients with grade II transitional cell carcinomas into a low risk and high risk group.

Carcinoma, Transitional Cell

[Unilateral testicular tumor in adrenogenital syndrome].

In male patients with congenital adrenogenital syndrome (AGS), in addition to the well known adrenal changes, tumor-like testicular proliferations may be observed. They have been known from literature since decades, but have become rare due to modern therapy. Especially in the mild and inapparent cases of AGS, the "tumors" cause clinical and morphological problems. The case of a 34 year old male AGS patient is presented, who underwent resection of a large adrenal cortical adenoma at age 28. Six years later, orchiectomy followed because of a testicular tumor. In frozen sections, the "Leydig cell-like" tumor caused diagnostic difficulties. After usual embedding and examination, the diagnosis of testicular "tumor" in AGS was confirmed. By review of the literature, pathomorphogenesis and morphology of these testicular tumors as well as possible histogenesis of their cells are discussed. Because of the close similarity to Leydig cell tumors, this most important differential diagnosis is especially considered. As a rule, testicular tumors in AGS are no indication for orchiectomy.

Adrenal Hyperplasia, Congenital

Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.

Routinely processed normal, hyperplastic and neoplastic prostatic tissue was immunohistochemically investigated with antibodies against chromogranin A and B and secretogranin II. In normal and hyperplastic prostates all three peptides were immunolocalized in scattered neuroendocrine cells situated within the glandular epithelium. In 17 prostatic carcinomas with pronounced neuroendocrine differentiation and in a case of prostatic carcinoid, chromogranin B was the major component whereas chromogranin A and secretogranin II were virtually absent in poorly differentiated (grade III) tumours. Neuroendocrine differentiation in prostatic cancer is most likely to be associated with a poor clinical outcome; thus, chromogranin B appears to be a useful marker in the histopathological diagnosis of these neoplasms.

Chromogranin A

Pharmacological characterization of metabotropic glutamate receptors in several types of brain cells in primary cultures.

Several cDNAs coding for metabotropic glutamate receptors (mGluR1-7) have now been isolated. mGluR1 and -5 are positively coupled to phospholipase C, whereas mGluR2, -3, -4, -6, and -7 are negatively coupled to adenylyl cyclase (AC) when they are expressed in Chinese hamster ovary or baby hamster kidney cells. However, the exact transduction mechanisms of these receptors in their natural environment remain to be determined. In a previous work, we demonstrated that striatal neurons in primary culture expressed a mGluR that is negatively coupled to AC and that has a pharmacology different from that of mGluR2. In the present study, the pharmacology of mGluRs negatively coupled to AC in several neuronal types and in glial cells was compared with the pharmacology of mGluR2, -3, and -4. Like striatal neurons, cerebral cortical neurons express a mGluR that is able to inhibit AC both in intact cells and in membrane preparations, via a pertussis toxin-sensitive G protein. This mGluR has a pharmacological profile similar to that of mGluR3, because quisqualate is active at relatively low concentrations (EC50 < 100 microM). Similar experiments revealed that cerebellar granule cells expressed mGluR2-like and mGluR4-like receptors. Striatal glial cells also expressed a mGluR negatively coupled to AC via a pertussis toxin-sensitive G protein. However, only glutamate and aspartate, and not quisqualate, 2-(carboxycyclopropyl)glycine, trans-1-aminocyclopentane-1,3-dicarboxylate, or L-2-amino-4-phosphonobutyrate, were agonists for this glial mGluR. This pharmacology is different from that of any cloned mGluR. Reverse transcription associated with polymerase chain reaction revealed that mGluR2 and mGluR3 mRNAs are present in striatal, cortical, and cerebellar neurons but not in striatal glial cells. Interestingly, mGluR4 mRNA was found at a high level in cerebellar granule cells and at a lower level in cortical neurons and glial cells. However, the mGluR4-specific agonist L-2-amino-4-phosphonobutyrate was found to inhibit AC very slightly in granule cells only. In conclusion, our data show that mGluR2- and mGluR3-like receptors can directly inhibit AC in neurons, and they raise the question of whether mGluR4 is really negatively coupled to AC in its normal environment. We also present evidence for a new mGluR subtype expressed in glial cells.

Adenylate Cyclase Toxin

Future directions in research of prostate carcinoma.

Histological, cytological and growth characteristics of prostate carcinoma are presented in this review, as well as the importance of various cell kinetic methods such as autoradiography, DNA- and AgNOR-analysis. By combining these methods with nucleolar grading, carcinoma of the prostate can be divided into two different groups of malignancy regarding therapy and prognosis: I. Carcinoma patients with well differentiated carcinomas and low risk. II. Carcinoma patients with poorly differentiated carcinomas and high risk. Cytogenetic and oncogenetic findings are discussed according to these groups. Special features of neuroendocrinically differentiated carcinomas are also presented. This review contains our own data in addition to information from the literature, and it describes future directions in the research of prostate carcinoma. Prostatic carcinoma is at present the second most common tumor in males. This has led to extensive research and numerous clinical studies on the prostate gland in the recent years.

Carcinoma

[Significance of AgNOR analysis of urothelial carcinomas].

Biopsies of normal and atypical/dysplastic epithelium of the urinary bladder as well as transitional cell carcinomas grades I to III were stained with a silver nitrate solution, and the silver-stained nucleolar organizer regions were evaluated. The AgNOR-analysis shows highly significant differences in the G II subgroups, similar to the results of nucleolar subgrading. Because of the significantly differing 5-year survival rates, it can be justified to divide transitional cell carcinomas into two groups: a low-risk group with favorable prognosis (G Ia to G IIa), and a high-risk group with poor prognosis (G IIb to G IIIa,b).

Biopsy

[AGNOR analyses of prostate carcinomas of high and malignancy].

Biopsies of normoglandular prostate, of hyperplastic-atypical/preneoplastic prostate and of prostatic carcinomas of different grades of malignancy were stained according to the method described by Crocker and Ploton in order to demonstrate the silver stained nucleolar organizer regions (AgNORs). The AgNOR values per unit area of nucleus were compared to the nucleolar status. Increased grade of malignancy corresponds to an increase in the number of AgNORs per unit area of nucleus. Significant differences in the AgNOR values exist particularly in the subgroups of grade II of malignancy, as well as between grades G Ia through G IIa vs. G IIb through G III. Differentiating prostatic carcinoma into low and high states of malignancy is important not only for prognosis, but also for the therapy, since, when tumor-biological aspects are considered, a radical prostatectomy is no longer indicated in patients with highly malignant carcinomas.

Cell Nucleolus

Grading and prognostic significance of urologic carcinomas.

The extent of surgical therapy of urological tumors and the intensity of post-surgical or primary chemo- or radiotherapy are dependent on staging and grading. Since the proliferative activity determines the size of the tumor, the primary prognostic evaluation corresponds with the grading. The histologic, cytologic, immunohistochemical and cell kinetic methods of examinating urological tumors are discussed considering their significance. Two tumor subgroups of malignancy are differentiated, one with a low risk and one with a high risk. The tumor group of intermediate malignancy (G II) consists of a mixture of both prognostic groups. Possibilities of an easy-to-use subgrading are given in order to differentiate a particular group from other subgroups at risk. A clear distinction between two subgroups of urologic tumors, namely with high or low malignancy, is a presupposition for the successful application of a differentiated therapy nowadays. Prognostic studies have corroborated this tumor subdivision.

Carcinoma, Renal Cell

[Synthesis of partial structure of complex types of N-glycoproteins].

Comparable syntheses of beta-D-GlcpNAc-(1----2)-[beta-D-GlcpNAc-(1----6)]-alpha-D-Manp-(1- ---6)-beta-D-ManpO(CH2)8CO2Me and beta-D-GlcpNAc-(1----2)-alpha-D-Manp-(1----3)-beta-D-ManpO(C H2)8CO2Me with the glycosyl halide and imidate methods were investigated. 3,4,6-Tri-O-acetyl-2-deoxy-(2,2,2-trichloroethoxycarbonylamino)-al pha-D-glucopyranosyl bromide or trichloroacetimidate are suitable glycosyl donors for beta-D-glycoside coupling with secondary hydroxyl groups.

Carbohydrate Sequence

Histological and immunohistochemical findings of prostatic carcinoma after external or interstitial radiotherapy.

In a retrospective study, the extent of reactions of different types of prostatic carcinomas to external or interstitial radiotherapy was compared with reactions to hormonal therapy. It is shown that prostatic carcinomas of different grades of differentiation can be divided into two main subgroups with distinctly different survival rates; i.e., prostatic carcinomas grades of malignancy Ib/IIa and grades IIb/III. Within an observation time of 10 years, the prostatic carcinoma grade of malignancy Ib/IIa shows a good response to external and interstitial radiotherapy. None of the patients died of the prostatic carcinoma. In the more poorly differentiated prostatic carcinomas, 2 out of 11 patients with external radiotherapy died of the carcinoma. The death rates from disease after hormonal therapy were higher, and the survival times were very short without therapy. Regressive changes are much more distinctly expressed in the better-differentiated carcinoma group. Differential diagnostic difficulties between regressive changes in carcinomatous glands and normal glands could be resolved by immunohistochemical proof of high-molecular-mass cytokeratin in basal cells.

Follow-Up Studies

Nucleolar grading of renal cancer. Correlation of frequency and localization of nucleoli to histologic and cytologic grading and stage of renal cell carcinomas.

Cytologic-nucleolar grading of carcinomas includes mitotic frequency, mean nuclear size, nuclear variability, degree of chromasia and nucleolar frequency, and the occurrence of singular or multiple, small or large nucleoli in the central or peripheral location. A total of 186 renal cell carcinomas were analyzed cytologically in this respect. The results were correlated to the histologic pattern, tumor stage, and grading. Renal cell carcinomas of low malignancy and stage possess a low nucleolar frequency and small solitary nucleoli in the central location. Highly malignant carcinomas (T3 or T4) are characterized by high nucleolar frequency and multiple prominent nucleoli in the eccentric position. There is no correlation to the histologic pattern. Therefore, the nucleolar status is helpful in grading and determination of prognosis of renal cell carcinomas.

Carcinoma, Renal Cell